Angle’s Newland reflects on excellent year as cancer patient trials advance

Angle Plc (LON:AGL, OTCMKTS:ANPCY) is poised to revolutionise cancer treatment with its Parsortix system, here we catch up with chief executive Andrew Newland.

As Newland explains Parsortix can capture cancer cells from blood, which is very significant for the emerging field of personalised medicine as it enables tests for specific cancer cells and means doctors can ensure the right treatment is administered to the patient.

Following the release of Angle’s financial results Newland reflects on what he calls “an incredible year” and he also discusses first commercial sales, a stream of ‘excellent published evidence’ from third parties and the start of major patient studies.

“We’ve got a 200 patient study in Europe running with four big cancer centres … and we’ve just recently announced a similar study in the United States,” he added.

Newland says these are substantial trials and, depending upon patient accrual, he expects results from the European study by the end of this calendar year with the US results following a few months after that.

Quick facts: ANGLE PLC

Price: 48.5 GBX

Market: AIM
Market Cap: £83.81 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...


ANGLE chief highlights latest positive Parsortix data from USC

An American study has raised the prospect of a new UK-developed blood test taking the place of painful biopsies in metastatic breast cancer. The University of Southern California (USC) Norris Comprehensive Cancer Center has been working with the Parsortix device, developed by AIM-listed...

on 04/18/2016

2 min read